Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI

Radiation therapy (RT) is used to treat approximately 50% of all cancer patients. However, RT causes a wide range of adverse late effects that can affect a patient's quality of life. There are currently no predictive assays in clinical use to identify patients at risk of normal tissue radiation toxicity. This study aimed to investigate the potential of Fourier transform infrared (FTIR) spectroscopy for monitoring radiotherapeutic response. Blood plasma was acquired from 53 prostate cancer patients at five different time points: prior to treatment, after hormone treatment, at the end of radiotherapy, two months post radiotherapy and eight months post radiotherapy. FTIR spectra were recorded from plasma samples at all time points and the data was analysed using MATLAB software. Discrimination was observed between spectra recorded at baseline versus follow up time points, as well as between spectra from patients showing minimal and severe acute and late toxicity using principal component analysis. A partial least squares discriminant analysis model achieved sensitivity and specificity rates ranging from 80% to 99%. This technology may have potential to monitor radiotherapeutic response in prostate cancer patients using non-invasive blood plasma samples and could lead to individualised patient radiotherapy.

Faraday Discuss. 2016 Jun 23;187:213-34. (PMID: 27043923)
J Biophotonics. 2009 Feb;2(1-2):13-28. (PMID: 19343682)
J Clin Oncol. 2009 Aug 20;27(24):3916-22. (PMID: 19620493)
Eur Urol. 2014 Apr;65(4):816-24. (PMID: 23453420)
J Alzheimers Dis. 2013;34(4):911-20. (PMID: 23302656)
Br J Cancer. 2012 Aug 7;107(4):748-53. (PMID: 22767148)
Anal Biochem. 2013 Feb 15;433(2):102-4. (PMID: 23079505)
Hum Mol Genet. 2008 Oct 15;17(R2):R102-8. (PMID: 18852197)
Am J Mens Health. 2019 Mar-Apr;13(2):1557988319846328. (PMID: 31023130)
Cancer Detect Prev. 2007;31(3):244-53. (PMID: 17646059)
Genome Med. 2011 Aug 23;3(8):52. (PMID: 21861849)
Br J Cancer. 2001 Apr 6;84(7):892-6. (PMID: 11286467)
Radiat Res. 2010 Feb;173(2):225-37. (PMID: 20095855)
Analyst. 2013 Jul 21;138(14):3917-26. (PMID: 23325355)
Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
Radiother Oncol. 1986 Apr;5(4):303-10. (PMID: 3726167)
Oncotarget. 2018 Apr 10;9(27):19368-19378. (PMID: 29721209)
Tumour Biol. 2017 Jul;39(7):1010428317717984. (PMID: 28671054)
Nat Genet. 2014 Aug;46(8):891-4. (PMID: 24974847)
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Dec 5;187:87-91. (PMID: 28666157)
Radiother Oncol. 2014 May;111(2):178-85. (PMID: 24785509)
Can Fam Physician. 2013 Dec;59(12):1269-74. (PMID: 24336537)
Int J Cancer. 2011 Dec 15;129(12):2928-34. (PMID: 21491423)
Algorithms Mol Biol. 2011 Dec 05;6(1):27. (PMID: 22142365)
Nature. 2007 Jun 28;447(7148):1087-93. (PMID: 17529967)
DNA Repair (Amst). 2012 Jan 2;11(1):12-21. (PMID: 22112864)
Cancer Manag Res. 2010 Oct 11;2:243-53. (PMID: 21188116)
J Res Med Sci. 2013 Jul;18(7):580-2. (PMID: 24516490)
Anal Chem. 1972 Sep 1;44(11):1906-9. (PMID: 22324618)
Int J Mol Sci. 2014 Apr 17;15(4):6609-24. (PMID: 24747595)
Nat Protoc. 2006;1(5):2315-9. (PMID: 17406473)
Cancer Lett. 2016 Nov 1;382(1):95-109. (PMID: 26944314)
J Natl Compr Canc Netw. 2010 Feb;8(2):211-23. (PMID: 20141678)
Mutat Res. 2010 Apr-Jun;704(1-3):108-14. (PMID: 20096806)
Anal Bioanal Chem. 2011 Nov;401(9):2919-25. (PMID: 21931952)
Hum Mol Genet. 2008 Oct 15;17(R2):R109-15. (PMID: 18852198)
Neuroimage. 2011 May 15;56(2):455-75. (PMID: 20656037)
Br J Cancer. 1993 Oct;68(4):819-23. (PMID: 8398714)
EBioMedicine. 2016 Aug;10:150-63. (PMID: 27515689)
Int J Radiat Biol. 2019 Jan;95(1):44-53. (PMID: 29528761)
Anal Chim Acta. 2015 Jun 16;879:10-23. (PMID: 26002472)
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1084-1092. (PMID: 26072091)
Nat Genet. 2008 Mar;40(3):316-21. (PMID: 18264097)
Analyst. 2015 Apr 7;140(7):2273-9. (PMID: 25599976)
Analyst. 2015 Apr 7;140(7):2280-6. (PMID: 25622686)
Cancer. 2011 Apr 1;117(7):1429-37. (PMID: 21425143)
Hum Mol Genet. 2008 Oct 15;17(R2):R116-21. (PMID: 18852199)
Appl Spectrosc. 2018 Jul;72(7):987-1000. (PMID: 29569946)

GOIPG/2016/1538 Irish Research Council; 11/RFP.1/BMT/3317 Ireland Science Foundation Ireland; 249689 EU FP7 Network of Excellence DoReMi

Keywords: Fourier transform infrared spectroscopy; blood plasma; high throughput; prostate cancer; radiotherapy; toxicity

Date Created: 20190705 Latest Revision: 20231013

20231013

PMC6679106

10.3390/cancers11070925

31269684